MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

106.96
-0.46
-0.43%
After Hours: 107.13 +0.17 +0.16% 16:30 02/21 EST
OPEN
107.29
PREV CLOSE
107.42
HIGH
108.44
LOW
106.71
VOLUME
528.31K
TURNOVER
--
52 WEEK HIGH
128.94
52 WEEK LOW
74.31
MARKET CAP
4.69B
P/E (TTM)
-48.5189
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of UTHR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average UTHR stock price target is 122.22 with a high estimate of 237.00 and a low estimate of 80.00.

EPS

UTHR News

More
  • Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
  • Zacks · 1d ago
  • Earnings Preview: United Therapeutics (UTHR) Q4 Earnings Expected to Decline
  • Zacks · 3d ago
  • Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics
  • Zacks · 3d ago
  • United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020
  • PR Newswire · 3d ago

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About UTHR

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
More

Webull offers kinds of United Therapeutics Corporation stock information, including NASDAQ:UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions.